New three-year real-world data on Leqembi® presented at CTAD 2026
Stockholm, Sweden, November 18, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new results from the real-world Lecanemab in Early Alzheimer’s Disease (LEADER) study[1]. The data showed that patients treated with Leqembi had a 76% lower rate of progression to moderate or severe Alzheimer’s disease dementia compared with a matched natural history cohort through 36 months of treatment. The new analysis included 560 patients treated with Leqembi across 13 clinical sites in the US.
The data were presented at the 19th Clinical Trials on Alzheimer’s Disease (